Page last updated: 2024-11-07

glycyl-arginyl-glycyl-aspartyl-seryl-proline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

glycyl-arginyl-glycyl-aspartyl-seryl-proline: can duplicate the binding activity of fibronectin vitronectin; RN given refers to ALL-L isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID115346
MeSH IDM0162322

Synonyms (15)

Synonym
gdrgdsp
91037-75-1
97047-91-1
grgdsp
l-proline, 1-(n-(n-(n-(n2-glycyl-l-arginyl)glycyl)-l-alpha-aspartyl)-l-seryl)-
glycyl-arginyl-glycyl-aspartyl-seryl-proline
l-proline, glycyl-l-arginylglycyl-l-alpha-aspartyl-l-seryl-
111844-24-7
h-gly-arg-gly-asp-d-ser-pro-oh
NTEDOEBWPRVVSG-FQUUOJAGSA-N
n-(2-{[2-({2-[(2-amino-1-hydroxyethylidene)amino]-5-carbamimidamido-1-hydroxypentylidene}amino)-1-hydroxyethylidene]amino}-3-carboxy-1-hydroxypropylidene)serylproline
DTXSID40914197
gly-arg-gly-asp-d-ser-pro
(s)-1-((6s,12s,15r)-1-amino-6-(2-aminoacetamido)-12-(carboxymethyl)-15-(hydroxymethyl)-1-imino-7,10,13-trioxo-2,8,11,14-tetraazahexadecane)pyrrolidine-2-carboxylic acid
(2s)-1-[(2r)-2-[[(2s)-2-[[2-[[(2s)-2-[(2-aminoacetyl)amino]-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carboxylic acid

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
"To evaluate the effects of transarterial administration of an integrin antagonist, GRGDSP (Gly-Arg-Gly-Asp-Ser-Pro), combined with transarterial chemoembolization (TACE) to treat hepatic carcinoma in rats."( Experimental study on transarterial administration of GRGDSP combined with transarterial chemoembolization in rats with hepatic carcinoma.
Feng, G; Liang, H; Qian, J; Wang, Y; Yin, J,
)
0.13
"Transarterial infusion of GRGDSP combined with TACE noticeably inhibited the growth of hepatic carcinoma and intrahepatic metastases in rats."( Experimental study on transarterial administration of GRGDSP combined with transarterial chemoembolization in rats with hepatic carcinoma.
Feng, G; Liang, H; Qian, J; Wang, Y; Yin, J,
)
0.13
"Transarterial administration of integrin inhibitor loaded nanoparticles combined with TACE evidently retards tumor growth and intrahepatic metastases compared with TACE alone or TACE plus integrin inhibitor in an animal model of hepatocellular carcinoma."( Transarterial administration of integrin inhibitor loaded nanoparticles combined with transarterial chemoembolization for treating hepatocellular carcinoma in a rat model.
Imlau, U; Oppermann, E; Qian, J; Qian, K; Tran, A; Vogl, TJ, 2016
)
0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (156)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (3.21)18.7374
1990's84 (53.85)18.2507
2000's45 (28.85)29.6817
2010's22 (14.10)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.69

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.69 (24.57)
Research Supply Index5.10 (2.92)
Research Growth Index5.79 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.69)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.62%)5.53%
Reviews3 (1.85%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other158 (97.53%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]